VEGFA and cancer: The cardiotoxicity rates range from 0.06% to 1.14% in patients undergoing antineoplastic drug treatment.[3] Although VEGF inhibitors have become one of the most promising strategies in cancer therapy, cardiovascular safety has been the most challenging aspect of anti-VEGF/VEGF receptor agent development and therapy.